Orchestra Biomed Holdings In (OBIO) — 13F Filings Explorer (Q2 2026)

OBIO ranks #5144 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

78 institutions disclose a position in OBIO, but none treat it as a major bet — even Propel Bio Management, LLC, its most concentrated holder, allocates just 2.0% of its own portfolio to it.

Daytona Street Capital LLC has added to its OBIO position for two straight quarters, increasing it by $508.4K to reach $743.8K today.

OBIO is up 1.2% today, and institutions have been net buyers of $28.0M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

OBIO reported a net loss of $59.0M over the trailing twelve months.

• Not yet profitable — net loss of $59.0M over the trailing twelve months
• Revenue grew 986.1% year over year
• Net income improved year over year, from -$69.7M to -$59.0M
• Operating cash flow was negative, using $49.0M in cash
• Current ratio of 6.45x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.96x equity — within a conventional range